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INTRODUCTION
Mesoangioblasts are mesodermal progenitors associated with vessels during the fetal stage of development and persist in post-natal life. They exhibit stem cell features such as pluripotency and self-renewal ability, and can differentiate, in vivo and in vitro, into different mesoderm cell types such as muscle, bone and adipocytes in response to specific extracellular cues [1, 2] . Upon injection into the arterial bloodstream, mesoangioblasts are capable of crossing the endothelium, migrate in the tissue interstitium and are then incorporated into regenerating skeletal muscle fibers. Such an action opens therapeutic perspectives for degenerative diseases of heart and skeletal muscles. In particular, mesoangioblasts have been successfully employed to correct morphologically and functionally the pathological alterations observed in the alphasarcoglycan null mice, a model of severe muscular dystrophy [3] . Moreover, it has been recently shown that mesoangioblasts repair the infarcted heart, being as effective as bone marrow progenitor cells in reducing postinfarction left ventricular dysfunction [4] . Despite these promising results, problems related with in vitro expansion, efficient engrafting and survival of mesoangioblasts in the toxic environment of the damaged muscle still hamper their therapeutic development [5] . The present knowledge of the extracellular agents capable of regulating key biological processes in mesoangioblasts is still limited. The characterization of the physiologically relevant agonists able of regulating proliferation and survival of these stem cells becomes fundamental to enhance their therapeutic efficacy. Studies of the last fifteen years have clearly demonstrated that sphingosine 1-phosphate (S1P), a sphingolipid metabolite physiologically present in the serum, is endowed with powerful biological activities [6, 7] . The bioactive sphingolipid is produced from the metabolism of sphingomyelin and although initially regarded as an intracellular mediator of growth factors and cytokines, it is presently recognized to elicit most of its effects as ligand of at least five different specific seven-spanning membrane receptors named S1P [1] [2] [3] [4] [5] [8] . A number of different studies have demonstrated that S1P regulates key biological processes such as cell proliferation, motility and survival in many different cell types. An important aspect of this regulation is that S1P receptors (S1PR) are differentially coupled to multiple G proteins upstream to distinct signaling pathways; thus, given that their expression pattern is highly cellspecific, S1P can exert different biological effects depending on the cell type. For example endothelial cells [9] and vascular smooth muscle cells [10] have been shown to proliferate in response to S1P; in contrast, in other cell types such as T lymphocytes [11] , hepatocytes [12] , and skeletal myoblasts [13] , the sphingolipid exerted an anti-proliferative effect. Although in seminal pioneering studies the mitogenic action of S1P had been reported to be independent from S1PR engagement [14] , it was subsequently found to implicate in many instances S1P 1 and/or S1P 3 [8] , whereas S1P 2 was identified as the receptor responsible for the antiproliferative properties of S1P [12, 13] . S1P appears also capable of increasing cell survival and inhibiting the apoptotic process in a number of different cell types [15, 16] . Notably, general attention in the dissection of the effects of S1P on cell proliferation and survival has been further increased by recent experimental work showing that a number of growth factors, cytokines and hormones generate S1P and that modulation of S1P metabolism is integral to their mitogenic and/or anti-apoptotic activity [6, 17, 18] . In this study we report that S1P is a potent mitogenic factor for mesoangioblasts and protects these cells from apoptosis induced by various stimuli such as serum deprivation, C 2 -ceramide or staurosporine treatment, supporting the view that S1P availability to these cells can be critical to improve their survival in vivo.
MATERIALS AND METHODS

Cell culture and treatment with agonists, antagonists and inhibitors
Murine mesoangioblasts [2, 3] were routinely grown in DMEM supplemented with heatinactivated 20% fetal calf serum (FCS) (Sigma, St. Louis, MO, USA). Human mesoangioblasts, isolated from adult muscle biopsies [19] , were routinely grown in Mega Cell (Sigma St. Louis, MO, USA) supplemented with heat inactivated 5% FCS and 5 ng/ml basic fibroblast growth factor (PeproTech, London, England) [20] . Cells were challenged with 1 μM D-erythro-S1P (Calbiochem, San Diego, CA, USA), (2 mM stock solution in dimethylsulfoxide). Specific antagonists of S1PR, VPC23019. [21] and JTE-013 [22] Alternatively, proliferation was evaluated by cell counting. Briefly, mesoangioblasts, seeded in 6-well plates at a density of approximately 1 x 10 5 cells, were serum-starved overnight and then challenged with 1 μM S1P for the indicated time-intervals before being trypsinized and counted by an hemocytometer.
RT PCR
One µg of total RNA extracted with TriReagent (Sigma, St. Louis, MO, USA) from murine mesoangioblasts was reverse transcribed into DNA as previously described [25] and subjected to PCR using the following software-designed oligonucleotides (Pharmacia Biotech, Uppsala, Sweden): S1P 1 forward 5'GTGTCCACTAGCATCCCGGAGGTTAAA GCTCTCCGCAGCTCA 3'; S1P 1 reverse 5' CCCAACAGGGGTAGCAGGAAGACCCC 3'; S1P 2 forward5'TCGCGAATG-CTGATGCTCATCGGG 3'; S1P 2 reverse 5' TCAGACCACCGTGTTGCCCTCCAG 3'; S1P 3 forward 5' GCAACCACGCATGCGCAGGGCCAC 3'; S1P 3 reverse 5' GCGGTTGTGAAATTTATTGTTTTTCCAG 3'; S1P 4 forward 5' CTGCTGCCCCTCTACTCCAA 3'; S1P 4 reverse 5' ATTAATGGCTGAGTTGAACAC 3'; S1P 5 forward 5'GAGCGCCACCTTACCATG 3'; S1P 5 reverse 5'GGAGCAGCTGGTGTCCAT 3' -actin forward 5'GCGGGAAATCGTGCGTGACATT 3'; -actin reverse 5' GATGGAGTTGAAGGTAGTTTCGTG 3'. PCR amplification products were separated on a 1.2% agarose gel.
Real time PCR
To quantify mRNA expression of S1P 1 , S1P 2 and S1P 3 real time quantitative RT-PCR (TaqMan PCR, Applied Biosystems, Weiterstadt, Germany) using the automated ABI Prism 7700 Sequence Detector System (Applied Biosystems, Foster City, CA) was performed essentially as previously described [26] . All samples were run in triplicate in Micro-Amp optical 96-well plates (Applied Biosystems) with a TaqMan Universal PCR Master Mix (Applied Biosystems). Simultaneous amplification of the target sequence (Assay on demand, S1P 1 Mm00514644_m1, S1P 2 Mm01177794_m1, S1P 3 Mm00515669_m1, Applied Biosystems, Foster City, CA) together with the housekeeping at Ospedale S. Raffaele on www.StemCells.com Downloaded from gene, 18S rRNA, was carried out with the following universal profile: initial denaturation for 10 min at 95 °C was followed by denaturation for 15 s at 95 °C, primer annealing and elongation at 60 °C for 1 min for 40-50 cycles. Results were analysed by ABI Prism Sequence Detection System software (version 1.7) (Applied Biosystems, Foster City, CA) and plotted by Microsoft Excel Software (Microsoft Excel Corp., New York, NY). The 2 -CT method was applied as a comparative method of quantification [27] .
Western blot analysis
Mesoangioblasts were lysed for 30 min at 4 °C in a buffer containing 50 mM Tris, pH 7.5, 120 mM NaCl, 1 mM EDTA, 6 mM EGTA, 15 mM Na 4 P 2 O 7 , 20 mM NaF, 1% Nonidet and protease inhibitor cocktail (1.04 mM AEBSF, 0.08 μM aprotinin, 0.02 mM leupeptin, 0.04 mM bestatin, 15 μM pepstatin A, 14 μM E-64) essentially as described in Donati et al. [13] . To prepare total cell lysates, cell extracts were centrifuged for 15 min at 10,000 g at 4 °C. Proteins (30 μg) from lysates were resuspended in Laemmli's sodium dodecylsulfate-(SDS) sample buffer. Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western analysis as previously described [13] . Bound phospho-p42/p44 MAPK and phospho-p38 MAPK antibodies (Cell Signaling Technology, Inc., Beverly, MA, USA) were detected using ECL reagents (Amersham Pharmacia Biotech, Uppsala, Sweden).
Apoptosis measurement
Mesoangioblasts were seeded at a density of approximately 1 × 10 5 cells/well and employed for experiments after 24 h. For serum-starvationand C 2 -ceramide-induced apoptosis, cells were incubated in serum-free medium in the presence or absence of 10 µM C 2 -ceramide (Sigma, St. Louis, MO, USA) for 24 h and when requested 1 µM S1P was administered 30 min and 18 h after serum starvation. For staurosporine-induced apoptosis, 0.5 µM staurosporine (Sigma, St. Louis, MO, USA) was added for the last 4 h of incubation to cells serum-starved for 24 h, treated or not at 30 min and 18 h incubation with 1 µM S1P. To quantitate DNA fragmentation the Cell Death Detection ELISA PLUS Kit (Roche Applied Science, Mannheim, Germany) was used to quantitatively determine in vitro cytoplasmic histone-associated DNA fragments characteristic of apoptotic cell death. The optical density was determined on an ELISA Reader using 405 and 490 nm (reference) filters. Alternatively, apoptosis was measured by caspase-3 activity assay. Briefly, cells were washed twice with PBS and then lysed for 20 min at 4°C in 20 mM Tris-HCl buffer, pH 7.4, containing 250 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 0.5 mM phenylmethylsulfonylfluoride, 4 mM sodium vanadate, and 1 mM DTT [28] . The lysis was completed by sonication, and total protein content was determined in the clarified lysates with the Coomassie Blue reagent (Bio-Rad, Hercules, CA, USA). Aliquots of total proteins (50 µg) were diluted in 50 mM HEPES-KOH buffer, pH 7.0, containing 10% glycerol, 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate, 2 mM EDTA, 10 mM DTT. Caspase-3 activity was determined by incubating the protein sample for 4 h at 37°C in the presence of 30 µ Ac-DEVD-AFC (excitation 400 nm, emission 505 nm) (Biomol Research Laboratories Inc. PA, USA). To determine nonspecific substrate degradation, the assays were also performed by preincubating total protein samples for 15 min at 37°C with or without the specific caspase inhibitor (200 nM Ac-DEVD-CHO) before substrate addition.
The apoptotic response was also evaluated by counting the trypsinized surviving cells by an hemocytometer.
In vivo cell survival assay D16-GFP mesoangioblasts [3] were pretreated with 1 μM S1P for 12 h, after which cells were suspended in culture medium. Delivery of mesoangioblasts was by injection of 5 x 10 5 cells directly into tibialis anterior muscles [29] . Muscles recovered from the mesoangioblasts- injected animals were dissected and frozen in liquid N 2 -cooled isopentane. Serial muscle sections were processed for TUNEL assay (Apoptag, Chemicon) to assess the presence of apoptotic nuclei and immunostained as previously described [3] with the anti-GFP antibody (Molecular Probes). The primary antibody was detected using appropriate secondary antibodies conjugated with Alexa 489 (Molecular Probes) and nuclei visualized with the DNA dye 4',6-diamidino-2-phenylindole (DAPI).
Statistical analysis
Data reported are means ±S.E.M. of triplicates of a representative experiment performed at least 3 times with analogous results. Statistical analysis was performed using Student's t test (* p < 0.05).
RESULTS
We initially evaluated the pattern of S1PR expression in murine mesoangioblasts. Amplified fragments of ~1000, 600, 225 bp corresponding to mRNA transcripts encoding for S1P 1 , S1P 2 and S1P 3 , respectively, were detected by RT-PCR analysis (Fig.1A) , while S1P 4 and S1P 5 were not (data not shown). Real-time PCR analysis revealed that the relative mRNA abundance was S1P 3 >>S1P 1 >S1P 2 (Fig.1B) .
The effect of S1P on mesoangioblast proliferation was evaluated by labeled thymidine incorporation assay experiments. The sphingolipid action was concentration-dependent with a maximal effect at 1 μM, and a halfmaximal effective concentration of 32.6 nM ± 7.1, n = 3 ( Fig.2A) . The mitogenic action of S1P was also confirmed by cell counting experiments, being the sphingolipid still capable of increasing cell number population up to 96 h of incubation (Fig. 2B) . Analogous results were obtained when cell proliferation in response to S1P treatment was evaluated in other independent mesoangioblast clones (A2 and A6) (data not shown). These results demonstrate that S1P behaves in these cells as full mitogen.
Since all the S1PRs that we found expressed by mesoangioblasts have been implicated in the proliferative response elicited by the sphingolipid in different cell types, we investigated the role of individual receptors by using selective agonists and antagonists. The selective S1P 1 agonist SEW2871 in the concentration range 1-30 μM did not trigger cell proliferation, excluding the involvement of S1P 1 in S1P-stimulated cell proliferation (Fig. 3A) . Pharmacological inhibition of S1P 2 using the selective antagonist JTE-013 reduced significantly S1P mitogenic effect, being the compound effective starting from 30 nM ( Fig  3B) . Instead, the S1P 1 /S1P 3 antagonist VPC23019 (100 nM) enhanced basal [ 3 H]thymidine incorporation and slightly reduced the proliferative action of S1P (Fig. 3  C) , suggesting a minor role, if any, for S1P 3 . On the whole these results indicate that the mitogenic action of S1P in mesoangioblasts occurs mostly via stimulation of S1P 2 receptor. Since the mitogenic effect of S1P can be accompanied by a pro-survival action of the sphingolipid, the potential anti-apoptotic effect of S1P in mesoangioblasts was also investigated. S1P fully prevented the formation of cytoplasmic histone-associated DNA fragments induced by 24 h culture under serum deprivation or in the presence of C 2 -ceramide (10 µM), and significantly reduced the amount of histone associated mono-and oligonucleosomes formed in response to staurosporine (0.5 µM) administration (Fig 4A) . Consistently, S1P significantly diminished the increase in caspase-3 activity and the reduction in total cell number induced by the different apoptogenic stimuli (Fig. 4B and C) . S1P exhibited a similar protective effect against apoptosis in mesoangioblasts clones A2 and A6 (data not shown).
To assess the pro-survival effect of S1P in vivo, the D16-GFP mesoangioblasts, previously treated with 1 μM S1P for 12 h, were injected directly into the right tibialis anterior muscle of -SG-null mice. Twelve hours later, treated and controlateral (control) muscles were removed and cell death assessed by staining with the TUNEL technique. As shown in Fig. 4D the dystrophic muscle showed signs of apoptosis and provoked cell death of injected GFP-positive mesoangioblasts. Mesoangioblast treatment with S1P before their injection reduced apoptosis by 51 ± 4.3 % (n = 4, P < 0.01 vs. NT), demonstrating also a clear-cut in vivo prosurvival action of the sphingolipid. The involvement of S1PR in the anti-apoptotic effect of S1P was next examined. As shown in Fig. 5, 1 μM SEW2871 did not prevent the staurosporineinduced formation of histone-associated DNA fragmentation, excluding the involvement of S1P 1 . Similarly, the protective effect of S1P was only slightly diminished by JTE-013 (1 μM) or VPC23019 (100 nM), ruling out a role also for S1P 3 or S1P 2 . Thus, the anti-apoptotic action of S1P appears to occur through S1PR-independent pathways. The possible molecular mechanisms involved in the biological effects exerted by S1P in mesoangioblasts were then investigated. In particular we studied the involvement of the MAP kinase (MAPK) signaling pathways that have been shown to be activated by S1P and have effect in both mitogenesis and apoptosis [9, [30] [31] [32] . To this end we used U0126 (10 μM) and SB203580 (5 µM), specific inhibitors of the p42/44 and p38 MAPK pathways, respectively. In control experiments the two inhibitors strongly reduced the S1P-induced activation of p42/44 MAPK and p38 MAPK, respectively (Fig. 6A ). In the same Figure it is also shown that cell incubation with 2 μM JTE-013 reduced p38 MAPK and p42/44 MAPK phosphorylation induced by 10 min treatment with 1 μM S1P. Cell treatment with U0126 (10 μM), significantly reduced basal [ 3 H]thymidine incorporation and attenuated the stimulation of DNA synthesis brought about by S1P; conversely, SB203580 (5 μM) did not affect the cell response to S1P (Fig. 6B) . Both U0126 and SB203580 did not influence the protective action of S1P during cell death (Fig. 6C) . These results indicate that S1P activates the p42/44 as well as the p38 MAPK pathway and that p42/44 MAPK is required for the mitogenic effect of S1P, while protection from apoptosis is independent from MAPK activation. Finally, in the perspective of a cell therapy in patients, it was evaluated whether the biological effects elicited by S1P in murine mesoangioblasts take place also in the same cell type isolated from human donors. As illustrated in Fig. 7A , treatment with 1 μM S1P significantly stimulated [ 3 H]thymidine incorporation into human mesoangioblasts. The sphingolipid was also found to strongly protect human mesoangioblasts from apoptosis. In particular, 1 μM S1P significantly reduced the formation of cytoplasmic monoand oligonucleosomes in response to 24 h serumdeprivation or 0.5 μM staurosporine administration (Fig.7B) . Notably, the mitogenic and antiapoptotic effect of the sphingolipid was comparable to that induced in murine cells.
DISCUSSION
This study represents the first experimental evidence for a key biological role of S1P in mesoangioblasts. In particular, S1P was found to promote cell proliferation and prevent programmed cell death.
The mitogenic effect exerted by S1P reported here is in agreement with a number of studies performed in different cell types in which the bioactive lipid is capable of stimulating cell proliferation and appears to depend on the action of S1P on its membrane receptors [8] [9] [10] . Murine mesoangioblasts were found to express S1P 1 , S1P 2 , S1P 3 , in agreement with the pattern of S1PR expression recently identified in human embryonic stem cells [33] . Although S1P 1 receptor is expressed in mesoangioblasts, it does not play a role in mitogenesis since the specific S1P 1 agonist SEW2871 was unable to reproduce the mitogenic action of the sphingolipid. This is a striking difference with the other cell types so far investigated in which this receptor plays a pivotal role in the sphingolipid-dependent cell proliferation [8] [9] [10] . Instead, the observed attenuation of the proliferative response to S1P by S1P 2 antagonist JTE-013 is in favour of a mitogenic role of S1P 2 while the modest inhibitory effect determined by S1P 1 /S1P 3 antagonist VPC23019 rules out a major role for S1P 3 in S1P-induced mesoangioblast proliferation. So far S1P 2 was found to be positively coupled to cell proliferation only in mesangial cells [32] , an interesting observation in light of the common perithelial niche of both mesangial cells and mesoangioblasts [19] ; in contrast, in other studies the same receptor resulted to be implicated in the anti-proliferative response elicited by the sphingolipid [12, 13] . This observation may have important implications in the in vitro expansion of these cells for therapeutic purposes, although selective S1P 2 agonists have not been developed yet. The study of the signaling pathways involved in the mitogenic effect of S1P highlighted a key role for p42/44 MAPK, in agreement with a number of other studies performed in different cells [9, 34, 35] .
Another important finding of this study is the powerful pro-survival effect exerted by S1P in mesoangioblast apoptosis induced by serum deprivation or treatment with C 2 -ceramide or staurosporine. S1P was found to fully prevent the DNA fragmentation caused by serum deprivation or C 2 -ceramide treatment, while chromatin damage induced by the more potent apoptogenic agent staurosporine was appreciably decreased by the sphingolipid. Moreover, S1P was capable of potently attenuating caspase-3 activation and counteracting the reduction in cell number induced by the apoptogenic stimuli. Furthermore, mesoangioblasts pretreated in vitro with S1P exhibited an increased survival when injected into tibialis anterior muscles of -SG null mice. On the whole these results demonstrate that S1P plays a key role in the prevention of in vitro programmed cell death of mesoangioblasts.
The molecular mechanisms implicated in the anti-apoptotic action of S1P appear complex and need further investigation. The pro-survival effect of the sphingolipid was not mimicked by the S1P 1 agonist SEW2871 and was not significantly influenced by S1PR antagonists VPC23019 or JTE-013, thus excluding the involvement of S1PR, and suggesting the possibility of an intracellular action of S1P [14, 36, 37] , since the exogenous sphingolipid may be transported across the plasma membrane, possibly via specific transporters [38] . However, at this stage it cannot be ruled out that the prosurvival effect of S1P in mesoangioblasts is due alternatively to G protein-coupled receptors different from S1PR, as already demonstrated in other cell systems [8, 39] .
Mesoangioblasts are presently regarded as very promising stem cells in the therapy of muscular dystrophy [3] . However, the reduced survival of these cells after injection in vivo is at least in part responsible for their partial ability to repopulate the damaged tissue, representing an obstacle to their employment in cell therapy. The present identification of S1P as powerful mitogenic and anti-apoptotic agent for mesoangioblasts suggests that their efficiency of muscle repair could be increased by the target delivery of exogenous S1P. In view of a future cell therapy it is noteworthy that S1P was here found able to stimulate proliferation of human mesoangioblasts and protect these cells from apoptosis.
Moreover, it has to be considered that S1P is present in the plasma of mammals in a concentration range of 0.1-0.6 μM [40] [41] , which is in principle sufficient to fully occupy the majority of S1PR borne by circulating cells. However, since the sphingolipid is largely bound to HDL fraction its real bioaivalability remains to be determined [42] . In agreement, it is of note that in vivo administration of S1P or S1P agonists is presently regarded as a valid therapeutical approach in a number of different pathologies ranging from renal failure to lung injury [43, 44] as well as to prevent transplant rejection and to treat autoimmune disorders [45] . 
A) Incorporation of [
3 H]thymidine. Serum-starved D16 mesoangioblasts were stimulated with various concentrations of S1P for 24 h. [ 3 H]thymidine (1 μCi/well) was added in the last 2 h of incubation. B) Cell counting. Serum-starved mesoangioblasts were stimulated with 1 μM S1P for the indicated times before being counted by an hemocytometer. Figure 3 . Role of S1PR in the proliferative action of S1P.
Effect of SEW2871 (A), JTE-013 (B) and VPC23019 (C) on mesoangioblast proliferation. The experimental conditions were those described in the legend to Fig.2 . Mesoangioblasts were incubated for 24 h in the presence of SEW2871 at the indicated concentrations or pre-incubated for 30 min in the presence of different concentrations of JTE-013 or 100 nM VPC23019 before being stimulated with 1 μM S1P for 24 h. 5 GFP-expressing mesoangioblasts pretreated with 1 μM S1P for 12 h were injected into the tibialis anterior muscles of 4-months-old -SG null mice. After 12 h muscles were recovered. Apoptosis of GFP-expressing mesoangioblasts was assessed by the TUNEL technique (images from one out of 4 reproducible experiments). Also shown is the DAPI staining of the nuclei and its overlay with the GFP and TUNEL staining. A)Western blot analysis of lysates (30 μg) of serum-starved mesoangioblasts incubated with or without 1 μM S1P for the indicated times in the presence or absence of 10 μM U0126, 5 μM SB203580 or 2 μM JTE-013. B) Effect of 10 μM U0126 or 5 μM SB203580 on the proliferative action of S1P in D16 mesoangioblasts. C) Effect of 10 μM U0126 or 5 μM SB203580 on the protective effect of S1P on staurosporine-induced DNA fragmentation.
